Discounted for Uncertain Pipeline Returns
Moderna trades at a discount because the market doubts its pipeline will deliver sustainable returns. ROIC at -18.5% is a red flag. In biotech, lasting capital returns matter most. This isn’t a bargain—just a risky bet.
Published by AssetNext · 2026-07-25
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-13 | Weak profile, strong price | 34 | -18.1% | +32.5% |
| 2026-07-13 | Weak profile, strong price | 35 | -18.1% | +36.5% |
| 2026-07-10 | Weak profile, strong price | 34 | -16.5% | +29.9% |
| 2026-07-10 | Weak profile, strong price | 35 | -16.5% | +37.1% |
| 2026-07-08 | Weak profile, strong price | 34 | -9.8% | +39.9% |
| 2026-07-08 | Weak profile, strong price | 35 | -9.8% | +46.6% |
| 2026-07-06 | Weak profile, strong price | 35 | 0.0% | +51.5% |
| 2026-07-06 | Weak profile, strong price | 35 | 0.0% | +53.6% |
| 2026-07-01 | Weak profile, strong price | 35 | 0.0% | +49.5% |
| 2026-06-30 | Weak profile, strong price | 35 | 0.0% | +40.5% |
Break down MRNA's structural position across all peer dimensions with the interactive app.